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BACKGROUND. RORa is a transcription factor which belongs to the family of orphan
nuclear receptors. The regulatory functions of this receptor are still poorly understood.
However, response elements for RORa are present on the promoter of cell cycle-related genes
suggesting that it might be involved in the control of cell proliferation. In this study, we
investigated the expression and the possible function of RORa in a human androgen-
independent prostate cancer cell line (DU 145). The thiazolidinedione-derivative CGP 52608
has been utilized as the speci®c ligand and activator of RORa.
METHODS. The effects of CGP 52608 on DU 145 cell proliferation and cell cycle distribution
were analyzed by hemocytometer and by FACS analysis, respectively. The expression of
RORa as well as the effects of RORa activation on the expression of cell cycle-related genes
were evaluated by RT-PCR. To clarify whether RORa activation might affect the proliferation
of prostate cancer cells also in vivo, nude mice bearing DU 145 tumor xenografts were treated
with CGP 52608 at different doses and the growth of the tumors was followed by caliper
measurement.
RESULTS. RORa is expressed in DU 145 cells and the treatment of the cells with the thiazo-
lidinedione-derivative CGP 52608 brought about a dose-dependent and signi®cant decrease of
cell proliferation. Ligand-induced activation of RORa affected cell cycle distribution, inducing
an accumulation in the G0/G1 phase and a decrease in the S phase. This effect was accom-
panied by an increased expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 and a
decreased expression of cyclin A. The growth of DU 145 tumors in nudemice was signi®cantly
reduced by treatment with CGP 52608.
CONCLUSIONS. These data indicate that, in androgen-independent DU 145 prostate cancer
cells, activation of the orphan nuclear receptor RORa inhibits cell growth, both in vitro and in
vivo. RORa also induces cell cycle arrest, possibly through the modulation of the expression of
cell cycle-related genes. Prostate 46:327±335, 2001. # 2001 Wiley-Liss, Inc.
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INTRODUCTION
The importance of the development of new anti-
cancer agents for the treatment of prostate carcinoma
is highlighted by the continuous increase of the
number of men diagnosed with this pathology. The
tumor of the prostate is, actually, the most frequent
malignancy and the second leading cause of male
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cancer deaths in the Western countries [1,2]. Prostate
cancer is usually androgen-dependent in its early
stages [3], when most patients positively respond to
the suppression of testosterone secretion and/or
action, which is mainly achieved through agonistic
analogs of LHRH and antiandrogens, given either
alone or in combination [3,4]. In later stages, after a
given time of tumor remission, a new phase of growth
appears in which surviving cancer cells have lost their
androgen dependence. In this situation, prostate
cancer hardly responds to conventional chemotherapy
and, therefore, an effective treatment is still lacking [5].
Orphan nuclear receptors constitute a large sub-
group of the superfamily of steroid/thyroid/vitamin
D/retinoid receptors, for which no endogenous ligand
has been identi®ed so far. A novel subclass of orphan
nuclear receptors is represented by the RORa family of
transcription factors, which comprises RZR (retinoid
Z receptor) a, ROR (retinoid acid receptor-related
orphan receptor) a1, 2 and 3, RZRb, and RORg. Sequ-
ence alignment showed that RZRa is an additional
splicing variant of RORa 1±3, whereas RZRb and
RORg are encoded by different genes [6±8]. The four
RORa splicing variants share common DNA- and
putative ligand-binding domains, but possess distinct
aminoterminal domains [8]. They bind preferentially
as monomers to a hormone-response element (RORE)
composed of a 6-base pair AT-rich sequence preceding
a half-site core motif PuGGTCA on the promoter of
target genes [7,8]. RORa has been shown to be expre-
ssed inmany peripheral tissues and cells, such as liver,
smooth muscle, testes, and peripheral blood lympho-
cytes [6]. This in contrast to RZRb, which has a brain-
speci®c distribution [9], and to RORg, which is mainly
found in skeletal muscle [10].
Though RORa is expressed in different tissues, its
involvement in possible physiological functions is still
poorly understood. The mutant mouse, staggerer, in
which the RORa gene is disrupted, exhibits cerebellar
abnormalities, demonstrating the crucial role played
by this receptor in the development of the cerebellum
[11]. RORa has been suggested to be involved in lipid
metabolism [12,13], to possess immunomodulatory
activity [14], and to mediate the antiarthritic properties
of a class of thiazolidinediones, of which CGP 52608 is
the lead compound [15,16]. ROREs have been identi-
®ed in the promoter region of cell cycle-related genes,
such as those of the cyclin-dependent kinase (CDK)
inhibitor p21WAF1/CIP1 [13] and of cyclin A (Dr. C.
Carlberg, Dusseldorf, Germany, personal communica-
tion), as well as in the promoter of N-myc [17], a gene
whose ampli®cation appears to be related to the
development of several tumors [18±20]. Taken toge-
ther, these observations suggest that the transcription
factor might be involved in the regulation of cell
growth and differentiation. In support of this observa-
tion, it has recently been reported that ligand-induced
activation of RORa signi®cantly reduces the growth of
the murine colon 38 adenocarcinoma [21].
In this study, we have investigated the expression
and the possible function of RORa in the proliferation
of a human androgen-independent prostate cancer cell
line (DU 145).
MATERIALSANDMETHODS
Materials
The thiazolidinedione derivative CGP 52608 was
kindly donated by Dr. I. Wiesenberg (Novartis, Basel,
Switzerland). This compound has been previously
demonstrated to speci®cally bind and activate RORa
[15,16].
Cell Culture and Proliferation Studies
The prostate cancer DU 145 cell line was obtained
from American Type Culture Collection (Rockville,
MD). DU 145 cells were routinely grown in RPMI-1640
medium (Seromed Biochrom, Berlin, Germany) sup-
plemented with 5% FBS (Gibco, Paisley, Scotland, UK),
glutamine (1 mM) and antibiotics (100 units/ml peni-
cillin G sodium, 100 mg/ml streptomycin sulphate) in a
humidi®ed atmosphere of 5% CO2/95% air. For proli-
feration studies, DU 145 cells were treated with CGP
52608 (from 0.01 to 1000 nM) for 7 days. At the end of
the treatment, cells were harvested and counted by
hemocytometer.
RT-PCR for RORa
In order to determine whether RORa receptors are
expressed in prostate cancer cells, RT-PCR was per-
formed on RNA extracts from DU 145 cells. After
phenol-chloroform extraction, 1 mg of total RNA from
each sample was used in a reverse transcription reac-
tion. cDNA synthesis was performed using the Gene
AMP kit (Perkin Elmer Cetus, Norwalk, CT), with an
oligo(dT)16 as a primer for the reverse transcriptase.
Samples containing cDNAs were then ampli®ed in a
100 ml solution containing PCR buffer (50 mM KCl,
10 mM Tris±HCl), 2 mM MgCl2, 15 pmol of a pair of
speci®c primers and 2.5 U Taq Polymerase. Thirty-®ve
cycles of ampli®cation were performed in a program-
mable heat block (Perkin Elmer Cetus) (1-min denatu-
ration at 94C, 45-sec primer annealing at 45C, and
2-min primer extension at 72C). The primers were:
5 0-AACGGCGAGACTTCCCCAACTG-3 0 (sense, 637±
658) and 5 0-CAAAGGCACGGCACACTCTGATAA-3 0
(antisense, 950±973) [22]. After RT-PCR, the ampli®ed
DNA products were separated on a 1.5% agarose gel
and stained with ethidium bromide. Southern blot
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analysis was performed and the blots were hybridized
with a synthetic 32P-labeled oligonucleotide probe:
5 0-GGGAGCTGATGTGGCAATTG-3 0 (803±822).
FACSAnalysis
Fluorescence-activated cell sorting (FACS) analysis
was performed as described [23]. DU 145 cells were
plated at a density of 400 cells/cm2 in 100-mm dishes
in RPMI-1640 supplemented with 5% FBS. Twenty-
four hours after plating, the cells were treated either
with vehicle or with CGP 52608 (1 and 100 nM) for
48 hr. After the treatment, DU 145 cells were try-
psinized, washed twice with ice-cold PBS, ®xed by
drop-wise addition of 70% ethanol and incubated at
4C overnight with constant agitation. Thirty minutes
before ¯ow cytometric analysis, the cellular double-
stranded nucleic acids were stained with propidium
iodine (50 mg/ml). RNAse (100 units/ml) was inclu-
ded to degrade double-stranded RNA. Propidium
iodine ¯uorescence was obtained using linear ampli-
®cation with doublet discrimination. Five thousand
forward scatter gated events were collected per
sample. Data were analyzed by the Cellquest program
(Becton-Dickinson, San Jose, CA).
RT-PCR forp21WAF1/CIP1and for CyclinA
In preliminary experiments, RT-PCRwas utilized to
verify the expression of the mRNAs for p21WAF1/CIP1,
cyclin A and b-actin (as an internal standard) in DU
145 cells. Extraction of total RNA from DU 145 cells
and RT-PCR were conducted as previously described
for RORa expression. Primers were as follows:
p21WAF1/CIP1 sense 5 0-GTGAGCGATGGAACTTCG-
A-3 0 and antisense 5 0-AATCTGTCATGCTGGTCTGC-
3 0 [24]; cyclin A sense 5 0-ATTAGTTTACCTGGACC-
CAG-3 0 and antisense 5 0-CACAAACTCTGCTACTT-
CTG-3 0 [25]; b-actin sense 5 0-TGACGGGGTCACCCA-
CACTGTGCCCATCTA-3 0 and antisense 5 0-CTAGA-
AGCATTTGCGGTGGACGATGGAGGG-3 0 [26]. PCR
ampli®cation was performed for 35 cycles (1-min
denaturation at 94C, 45-sec primer annealing at 60C
and 2-min primer extension at 72C). cDNA products
were separated on 1.5% agarose gel and stained with
ethidium bromide. To con®rm the speci®city of the
cDNAs obtained, RT-PCR products were Southern
blotted and the blots were hybridized with 32P-labeled
oligonucleotide probes, speci®c for the cDNA sequ-
ences of p21WAF1/CIP1, cyclin A, and b-actin, respec-
tively.
To choose the adequate number of cycles for the
ampli®cation of p21WAF1/CIP1, cyclin A, and b-actin
cDNAs, we performed RT-PCR on RNA extracted
from DU 145 cells using different numbers of
cycles: from 20 to 35. After RT-PCR, the ampli®ed
cDNAs were separated on an agarose gel, stained
with ethidium bromide, and photographed under UV
light.
To study the effects of ligand-induced activation of
RORa on the expression of cell cycle-related genes, DU
145 cells were plated in 100 mm dishes at a density of
15,000 cells/cm2. Twenty-four hours after plating, the
cells were treated with CGP 52608 (either 1 or 100 nM)
for 3, 6, 12, 24 or 36 hr. At the end of the treatment, the
cells were harvested, RNAs were extracted, and
submitted to RT-PCR at adequate cycles. Equal RT
reaction solutions were utilized in the PCR reaction in
the presence of the speci®c primers for p21WAF1/CIP1,
cyclin A, and b-actin. After RT-PCR, the relative int-
ensities of the cDNA bands were quantitated by
computer-assisted densitometric scanning using the
Image program, and p21WAF1/CIP1 and cyclin A cDNA
levels were standardized to b-actin cDNAs at the
corresponding time intervals.
TumorGrowth Studies
Experiments were carried out using male athymic
CD1 nude mice, 9 weeks old (Charles River, Calco,
Italy). Animals were maintained in laminar ¯ow
rooms, keeping temperature and humidity constant.
Experimental protocols were approved by the Ethic
Committee for Animal Experimentation of the Nat-
ional Cancer Institute (Milano, Italy) according to the
U.K. Coordinating Committee on Cancer Research
Guidelines [27]. DU 145 cells were inoculated sub-
cutaneously from in vitro cell cultures (8 106/0.2 ml
medium/¯ank). In all the experiments performed,
injection of the cells resulted in rapidly growing tum-
ors in 100% of animals. Each control or drug-treated
group included ®ve/six mice bearing bilateral tumors.
CGP 52608 was formulated at different concentrations
(from 0.01 to 10 mg/kg) by suspending it in an aqu-
eous solution of 0.5% methylcellulose/EtOH 5%. The
formulated solution was made fresh every 2±3 days
and administered daily per os (by gavage) in a volume
of 10 ml/kg body weight; control animals were treated
with solvent. This protocol is similar to the one used
by Dr. Wiesenberg and coworkers [16] to evaluate the
antiarthritic properties of CGP 52608. Tumor growth
was followed by assessing tumor volume: width2
length/2, every 3±4 days over the experimental frame.
Mice were weighed twice a week and their general
health was monitored during the entire experiment.
Experiment1
Mice were inoculated with DU 145 cells and drug
treatment was started on the same day of inoculum
(Day 0) and continued with a daily schedule for
2 weeks. The growth of tumors was followed by
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caliper measurement at different time intervals up to
18 days.
Experiment 2
Animals were inoculated with DU 145 cells (Day 0)
and CGP 52608 treatment (0.01±10 mg/kg) started
7 days after implantation (when tumors reached
approximately 80±90 mm3 in volume) and continued
up to Day 23 after cell inoculation with a daily sche-
dule. In this experiment, one mouse/group was sacri-
®ced by cervical dislocation on days 16 and 23; the
tumors were collected and processed for histological
examination. Samples were stained with hematoxylin
and eosin and evaluated by light microscopy for the
degree of in¯ammation and necrosis and for the
evaluation of apoptotic and mitotic cells.
Statistical Analysis
Statistical comparisons of the data were performed
using the Dunnett test [28] after one-way analysis of
variance.
RESULTS
Expression of RORa in DU145Cells
RT-PCR experiments demonstrated that the nuclear
orphan receptor RORa is expressed in DU 145 cells,
since the predicted 337-bp cDNA fragment hybridized
with a speci®c 32P-labeled oligonucleotide probe
(Fig. 1A, lane 1). The cDNA fragment was not seen
in reactions in which the reverse transcriptase was
omitted (Fig. 1A, lane 2).
Effects of RORaActivation onDU145 Cell
Proliferation
We investigated whether the ligand-induced acti-
vation of RORa might affect the proliferation of DU
145 cells. Exponentially growing DU 145 cells were
treated daily, for 7 days, with different doses of CGP
52608. The treatment brought about a signi®cant and
dose-dependent decrease of tumor cell proliferation
(Fig. 1B). The thiazolidinedione derivative was sig-
ni®cantly (P < 0:05) effective from 0.1 to 1000 nM, with
a half-maximal response at approximately 5 nM.
Effects of RORaActivation onCell Cycle
Distribution of DU145Cells
To investigate the possible mechanisms underlying
the antiproliferative effect related to RORa activation,
we ®rst assessed the effects of CGP 52608 (1 and
100 nM) on cell cycle distribution. FACS analysis indi-
cated that both doses of CGP 52608 caused a signi-
®cant (P < 0:05) and dose-dependent accumulation of
the cell populations in the G0/G1 phase of the cell cycle
and a decrease in S phase (Table I). Lower doses of the
compound were found to be ineffective (data not
shown). These experiments demonstrate that activa-
tion of RORa leads to cell cycle withdrawal in DU 145
cells.
Effects of RORaActivation onp21WAF1/CIP1and
CyclinAExpression inDU145Cells
Since CGP 52608 signi®cantly affects the distribu-
tion of DU 145 cells through the cell cycle, we inves-
tigated whether RORa activation might modulate the
expression of cell cycle-related genes, such as
Fig. 1. RORa is expressedinDU145cells anditsactivationresults
in reduced cell proliferation. (A) RT-PCR analysis of RZR/RORa
expression in DU 145 cells. Total RNA from DU 145 cells was
reverse-transcribedandamplfiedbyPCRin thepresenceof specific
oligonucleotide primers. After Southern blot, the 337 bp cDNA
fragment obtained specifically hybridized with the 32P-labeled
RORa oligonucleotide probe (lane 1). Lane 2, no reverse tran-
scription. (B) Inhibition ofDU145 cell growthbydifferentdoses of
CGP 52608. Data are expressed as the mean cell number/pla-
te SEM. P < 0:05 vs.Controls,C.
TABLE I. Effects of CGP 52608 onCell CycleDistributionof
DU145 Cells
Controls CGP 52608 CGP 52608
1 nM 100 nM
G0/G1 48.2 1.1 56.2 1.0* 65.7 1.8*
S 22.3 0.2 16.4 0.7* 9.6 0.6*
G2/M 28.4 1.3 27.8 0.9 31.1 0.4
*P < 0:05 vs. controls.
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p21WAF1/CIP1 and cyclin A. As already mentioned, in
the promoter of these genes a RORE has been pre-
viously identi®ed.
In preliminary experiments, we performed RT-PCR
analysis in the presence of speci®c oligonucleotide
primers for p21WAF1/CIP1, for cyclin A, and for b-actin
(as an internal standard). As expected according to the
primers used, cDNA products of 311, 443, and 660 bp
were obtained for the three genes, respectively
(Fig. 2A). After Southern blotting, the cDNA bands
hybridized with 32P-labeled oligonucleotide probes,
con®rming the speci®city of the ampli®ed cDNAs
(Fig. 2B ).
We then conducted RT-PCR at various cycles to
choose the adequate number of cycles for each gene.
The intensity of each band increased in parallel with
the increasing number of PCR cycles, as shown in
Figure 3. We concluded that the adequate number of
PCR cycles for p21WAF1/CIP1 and for b-actin was 20 and
that for cyclin A was 25.
To study the effects of RORa activation on the
expression of cell cycle-related genes, DU 145 cells
were treated with CGP 52608 (1 and 100 nM) for
different time intervals, from 3 to 36 hr. At the end of
the treatment, RT-PCR was performed on extracted
RNAs at adequate cycles. We found that, in control
cells, p21WAF1/CIP1 mRNA expression was slightly
expressed at all time intervals (Fig. 4A). CGP 52608,
at both doses, signi®cantly (P < 0:05) increased
p21WAF1/CIP1 mRNA levels at 6 hr (Figs. 4A, 5A). In
the absence of CGP 52608, cyclin A mRNA levels
remained at the basal level until 3 hr, but markedly
increased thereafter (Fig. 4B). The thiazolidinedione
derivative signi®cantly (P < 0:05) inhibited cyclin A
mRNA expression at 24 and 36 hr after plating (Figs.
4B, 5B). As expected, the levels of b-actin mRNA were
not affected by the treatment at any time interval
considered (Fig. 4C).
Effects of RORaActivation onDU145 Tumor
Growth inNudeMice
We investigated whether the activation of RORa
could affect the growth of prostate cancer cells also in
an in vivo setting.
In the ®rst experiment, DU 145 cells were injected
subcutaneously into the ¯ank of nude mice and the
treatment with CGP 52608 (0.01±10 mg/kg, daily by
gavage) was started the same day. Tumor volume was
measured at different time intervals, up to Day 18. A
signi®cant reduction in tumor volume was detectable
in mice treated with CGP 52608, at any dose, by Day
7 up to Day 11 (Fig. 6A). At these time intervals, the
Fig. 2. Expression of p21WAF1/CIP1, cyclin A, and b-actin inDU145
cells. Total RNA from DU 145 cells was reverse-transcribed and
amplified by PCR in the presence of specific oligonucleotide pri-
mers. (A) Ethidium bromide stained agarose gel of the amplified
cDNAs. (B) Autoradiography of the Southern blot obtained from
thegel shownin (A) after hybridizationwith specific 32P-labeled oli-
gonucleotide probes.Lane1, p21WAF1/CIP1; lane 2, cyclin A; lane 3,
b-actin; lane 4, RT-PCR control (308 bp); lane 5, no reverse tran-
scriptase; lanes 6 and 7,DNAmolecular weightmarkers III and V,
respectively (RocheDiagnostic,Monza, Italy).
Fig. 3. Intensities of PCR products for p21WAF1/CIP1, cyclin A, and
b-actin at various cycles. PCR amplifications were conducted at
various cycles startingwith equal RTreaction solutions.
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Fig. 4. Effects of RORa activation on cell cycle-related gene expression in DU145 cells.Cells were treatedwith CGP 52608 (1nM, middle
lane, and100 nM, lower lane) or with vehicle alone (upper lane).Total RNAwas extracted at the indicated times and analyzedby RT-PCR at
adequate cycles as described in`Materials andMethods' for p21WAF1/CIP1 (A), cyclin A (B) and, b-actin (C).
Fig. 5. Quantitativeanalysis of theeffectsofRORa activationoncellcycle-relatedgeneexpressioninDU145cells.Relativeintensitiesof the
bands shownin Fig.4were quantitatedbycomputer-assisteddensitometric scanningusing the Imageprogram, andp21WAF1/CIP1 (A) andcyclin
A (B) cDNA levels were standardized to b-actin cDNAs at the corresponding time intervals.* P< 0:05 vs.Controls at corresponding time
intervals.
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average tumor volume in CGP 52608-treated mice was
approximately 50% of that found in control mice. The
highest doses (1 and 10 mg/kg) were found to be
effective at later intervals also (Fig. 6A).
In the second experiment, DU 145 cells were inje-
cted subcutaneously into nude mice on Day 0, but the
treatment (0.01±10 mg/kg, daily, by gavage) was star-
ted only 7 days later, when the tumors were already
present (80±90 mg). The treatment lasted up to Day 23.
Figure 6B shows that a signi®cant reduction in tumor
volume was detectable up to Day 16, at all the doses of
CGP 52608 used. After this time interval, the treatment
was signi®cant on Day 18 at the doses of 0.1±10mg/kg
and on Day 21 at the dose of 10 mg/kg (Fig. 6B).
However, tumor volumes in treated animals remained
always lower than in control mice even if not signi-
®cantly, possibly due to the high variability of tumor
volumes at longer time intervals (Fig. 6B).
Histological examination of the tumors by light
microscopy revealed a comparable level of in¯amma-
tion and necrosis in control and treated tumors. More-
over, no sign of toxicity (as detected by body, spleen,
liver, lungs, seminal vesicles, and prostate weights)
was associated with CGP 52608 treatment (data not
shown).
DISCUSSION
In this study we have shown that RORa is expre-
ssed in androgen-independent DU 145 prostate cancer
cells and that its ligand-induced activation brings
about a signi®cant decrease in cell proliferation and
tumor growth. We have also shown that CGP 52608,
the speci®c ligand and activator of RORa, induces cell
cycle withdrawal by accumulating cells in the G0/G1
phase, and decreasing cells in the S phase.
Cell cycle arrest is obviously the result of a modi-
®cation of the expression and/or activity of factors
which play a crucial role in cell cycle progression. It is
known that progression through the cell cycle is
governed by a family of cyclins/CDKs complexes.
Each CDK can form binary complexes with several
cyclins and various cyclin/CDK complexes regulate
a distinct phase of the cell cycle [29]. Cyclin D1, by
complexing with CDK4, stimulates progression from
G1 to S; the activity of this complex is blocked by the
CDK inhibitor p21WAF1/CIP1 [29]. Cyclin A, which
starts being synthesized at the end of G1 phase, app-
ears abundantly at the G1/S transition, and triggers
the S phase [29,30]. Our data have shown that CGP
52608, by activating the RORa receptor, increases the
expression of p21WAF1/CIP1, thus blocking G1/S pro-
gression, and decreases the expression of cyclin A,
thus preventing the triggering of S phase. Therefore,
RORa activation in androgen-independent prostate
cancer cells seems to lead to growth arrest and to cell
cycle withdrawal, at least partially, through a modula-
tion of the expression of genes which are deeply
involved in the regulation of the cell cycle.
The molecular mechanisms through which RORa
might modulate the expression of p21WAF1/CIP1 and
cyclin A are still unknown. As already mentioned, this
receptor has been shown to bind preferentially as a
monomer to a RORE composed of a AT-rich sequence
preceding a half-site core motif PuGGTCA in the pro-
moter region of target genes [7,8]. Since this hexameric
consensus motif is recognized by most of the nuclear
receptors, it has been suggested that RORa might
regulate its target genes by competing with other tran-
scription factors, such as retinoid receptors, COUP-TF,
and PPAR for binding to DNA [13,31]. In line with this
observation, RORa has recently been shown to incre-
ase the transcriptional activity of the thyroid hormone
Fig. 6. Effects of the RORa ligand on the growth rate of DU145
tumors in nude mice. Animals were treated daily, by gavage, with
CGP 52608 at different doses. Data are expressed as the mean
tumor volume SEM. (A) Treatment was started simultaneously
with cell inoculation and lasted up to Day 14. (B) Treatment was
started 7 days after cell inoculation and lasted up to Day 23.
P< 0:05 vs.Controls at corresponding time intervals.
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receptor [32]. Whether RORa might affect the expres-
sion of p21WAF1/CIP1 and cyclin A through interac-
tion with other transcription factors is still an open
question.
The conclusion that RORa activation induces
growth arrest in androgen-independent DU 145 pro-
state cancer cells is further supported by in vivo
studies. We have shown that the thiazolidinedione
derivative CGP 52608 exerts a signi®cant dose-depen-
dent growth inhibition of DU 145 prostate cancer
xenografts in nude mice. A comparable response was
achieved treating early (Day 0) or advanced (Day 7)
tumors, possibly re¯ecting the cytostatic effect of the
receptor ligand. Our results are in line with the data
previously reported for a colon cancer cell line. As
mentioned in the Introduction, Karasek et al. [21] have
actually shown that the treatment of CGP 52608
inhibits the growth of the murine Colon 38 adenocar-
cinoma, both in vitro and in vivo. These observations,
together with our data, seem to suggest that activation
of RORa might be considered as the possible mole-
cular basis for the cytostatic activity of new anticancer
agents. Combinations between cytostatic and cytotoxic
agents are currently under study in clinical settings
due to the encouraging results obtained in preclinical
models [33]. Therefore, a possible combination of
compounds activating RORa with classical cytotoxic
chemotherapy to optimize the ef®cacy of the treatment
is worth being investigated. Interestingly, this nuclear
receptor has been reported to interact with the meta-
stasis suppressor candidate NM23 [34], suggesting
that it might be involved not only in the control of
cancer cell proliferation, but also in the regulation of
their metastatic potential. Studies are in progress in
our laboratory to verify this hypothesis.
On the basis of their deep involvement in important
cellular mechanisms, the identi®cation of speci®c
ligands for orphan nuclear receptors represents a
crucial step in the identi®cation of their physiological
functions. So far, no endogenous ligands for RORa
have been de®nitely identi®ed. Melatonin, the major
pineal gland hormone, which seems to possess onco-
static properties, has been shown to bind and activate
RORa, when transiently transfected in Drosophila cells
[9,35]. Moreover, Garcia-Maurino and coworkers have
shown that CGP 52608 can displace the binding of 125I-
melatonin to nuclear extracts of human lymphocytes
[14]. However, the possibility that the pineal gland
hormone might represent the endogenous ligand
for this class of receptors is still a matter of debate
[9,36].
In conclusion, ligand-induced activation of RORa,
plays a critical role in the control of the growth of
hormone-independent DU 145 prostate cancer cells,
either in in vitro or in in vivo systems.
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